Accurate Prediction of Drug-Induced Liver Injury Using Stem Cell-Derived Populations

Author:

Szkolnicka Dagmara1,Farnworth Sarah L.12,Lucendo-Villarin Baltasar1,Storck Christopher3,Zhou Wenli4,Iredale John P.5,Flint Oliver3,Hay David C.1

Affiliation:

1. Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom

2. FibromEd Products Ltd., Edinburgh Bio-Quarter, Edinburgh, United Kingdom

3. Department of Oncology, Second Military Medical University, Shanghai Changzheng Hospital, Shanghai, People's Republic of China

4. Discovery Toxicology, Bristol-Myers Squibb, Princeton, New Jersey, USA

5. Medical Research Council Centre for Inflammation, Edinburgh, United Kingdom

Abstract

Abstract Despite major progress in the knowledge and management of human liver injury, there are millions of people suffering from chronic liver disease. Currently, the only cure for end-stage liver disease is orthotopic liver transplantation; however, this approach is severely limited by organ donation. Alternative approaches to restoring liver function have therefore been pursued, including the use of somatic and stem cell populations. Although such approaches are essential in developing scalable treatments, there is also an imperative to develop predictive human systems that more effectively study and/or prevent the onset of liver disease and decompensated organ function. We used a renewable human stem cell resource, from defined genetic backgrounds, and drove them through developmental intermediates to yield highly active, drug-inducible, and predictive human hepatocyte populations. Most importantly, stem cell-derived hepatocytes displayed equivalence to primary adult hepatocytes, following incubation with known hepatotoxins. In summary, we have developed a serum-free, scalable, and shippable cell-based model that faithfully predicts the potential for human liver injury. Such a resource has direct application in human modeling and, in the future, could play an important role in developing renewable cell-based therapies.

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3